<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480360</url>
  </required_header>
  <id_info>
    <org_study_id>D17170</org_study_id>
    <nct_id>NCT03480360</nct_id>
  </id_info>
  <brief_title>Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression</brief_title>
  <official_title>Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor
      peripheral blood stem cells, rather than marrow. Clinical outcomes will be defined while
      focusing efforts on immune reconstitution focusing on immune checkpoint regulators after a
      related haploidentical stem cell transplant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>100-Day Survival</measure>
    <time_frame>100 days post date of peripheral blood transplant</time_frame>
    <description>Define 100-day survival of subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Checkpoint Regulators - Incidence</measure>
    <time_frame>Days 30, 60, and 90 post-transplant</time_frame>
    <description>To characterize the incidence of immune checkpoint regulators (V-domain Ig Suppressor of T-cell Activation, cytotoxic T-lymphocyte-associated protein 4 [CTLA], Programmed cell death protein 1 [PD-1]) during early immune recovery following an allogeneic stem cell transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloid-derived suppressor cells (MDSCs) after Graft vs. Host Disease (GVHD) diagnosis - checkpoint regulator expression</measure>
    <time_frame>Post-transplant through study completion or death, assessed up to 3 years post-transplant</time_frame>
    <description>In those patients experiencing GVHD, the study team will define the checkpoint regulator expression on MDSCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDSCs after GVHD diagnosis - peripheral blood mononuclear cells</measure>
    <time_frame>Post-transplant through study completion or death, assessed up to 3 years post-transplant</time_frame>
    <description>In those patients experiencing GVHD, the study team will define the peripheral blood mononuclear cells and myeloid subsets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDSCs after GVHD diagnosis - myeloid subsets using flow cytometry</measure>
    <time_frame>Post-transplant through study completion or death, assessed up to 3 years post-transplant</time_frame>
    <description>In those patients experiencing GVHD, the study team will define the myeloid subsets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDSCs after GVHD diagnosis - frequency</measure>
    <time_frame>Post-transplant through study completion or death, assessed up to 3 years post-transplant</time_frame>
    <description>In those patients experiencing GVHD, the study team will define the MDSCs frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Checkpoint Regulators - Prevalence</measure>
    <time_frame>Days 30, 60, and 90 post-transplant</time_frame>
    <description>To characterize the prevalence of immune checkpoint regulators (VISTA, CTLA-4, PD-1) during early immune recovery following an allogeneic stem cell transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Checkpoint Regulators - Function</measure>
    <time_frame>Days 30, 60, and 90 post-transplant</time_frame>
    <description>Flow cytometry will be used to characterize the function of immune checkpoint regulators (VISTA, CTLA-4, PD-1) during early immune recovery following an allogeneic stem cell transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Myelodysplasia</condition>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Myelofibrosis</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Plasma Cell Disorder</condition>
  <arm_group>
    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cyclophosphamide, fludarabine, total body irradiation, immune suppression including tacrolimus and cellcept, Granulocyte colony-stimulating factor (G-CSF), and peripheral blood transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)</description>
    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2 daily for 5 days</description>
    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>200 centigray (cGy) for one day (day -1)</description>
    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.</description>
    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cellcept</intervention_name>
    <description>dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.</description>
    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>g-csf</intervention_name>
    <description>5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) &gt; 1000/mcL for 3 days.</description>
    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Transplant</intervention_name>
    <description>cell dose goal: &lt; 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight</description>
    <arm_group_label>Johns Hopkins' conditioning regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: less than 75 years

          -  The patient must be approved for transplant by the treating transplant physician. This
             includes completion of their pre-transplant workup, as directed by standard
             Dartmouth-Hitchcock Medical Center (DHMC) Standard Operating Procedure (SOP) (DHMC SOP
             - Pre-transplant Evaluation of allogeneic recipient (Appendix).

          -  The patient must have a disease (listed below) with treatment-responsiveness that the
             treating transplant physician believes will benefit from an allogeneic stem cell
             transplant. The diseases include:

          -  Acute leukemia - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia

          -  Chronic leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia

          -  Myelodysplasia

          -  Myeloproliferative disorder

          -  Myelofibrosis

          -  Lymphoma - Non-Hodgkin's Lymphoma or Hodgkin's disease

          -  Plasma cell disorder, including myeloma, Waldenstrom's Macroglobulinemia

          -  Donor availability- the patient must have an identified RELATED haplo-identical donor

          -  No Human Immunodeficiency Virus infection or active hepatitis B or C

          -  Eastern Cooperative Oncology Group performance status: 0-2

          -  Diffusing capacity of carbon monoxide (DLCO) greater than or equal to 40 % predicted

          -  Left ventricular ejection fraction greater than or equal to 40%

          -  Serum bilirubin &lt; 2x upper limit of normal; transaminases &lt; 3x normal at the time of
             transplant

          -  No active or uncontrollable infection

          -  In female, a negative pregnancy test if experiencing menstrual periods

          -  No major organ dysfunction precluding transplantation

          -  No evidence of an active malignancy that would limit the patient's survival to less
             than 2 years. (If there is any question, the PI can make a decision).

        Exclusion Criteria:

          -  Psychiatric disorder or a mental deficiency of the patient that is sufficiently severe
             to make compliance with the treatment unlikely, and making informed consent
             impossible.

          -  Major anticipated illness or organ failure incompatible with survival from bone marrow
             transplant.

          -  History of refractory systemic infection

        DONOR ELIGIBILITY

          -  Human leukocyte antigen (HLA) haplo-identical matched related.

          -  The donor must be healthy and must be willing to serve as a donor, based on standard
             National Marrow Donor Program (NMDP) guidelines and DHMC SOP - Donor Evaluation
             (Appendix)

          -  The donor must have no significant co-morbidities that would put the donor at marked
             increased risk

          -  There is no age restriction for the donor

          -  Informed consent must be signed by donor

        DONOR EXCLUSION CRITERIA

          -  The NMDP guidelines for exclusion criteria will be used (Appendix). In addition, the
             following donors are NOT eligible:

          -  Pregnant or lactating donor

          -  HIV or active Hep B or C in the donor

          -  Donor unfit to receive G-CSF and undergo apheresis

          -  A donor with a psychiatric disorder or mental deficiency that makes compliance with
             the procedure unlikely and informed consent impossible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Meehan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Nurse</last_name>
    <phone>(800) 639-6918</phone>
    <email>cancer.research.nurse@dartmouth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Nurse</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michael Sainz</last_name>
      <phone>603-650-5153</phone>
      <email>michael.sainz@hitchcock.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014 Jul 17;124(3):334-43. doi: 10.1182/blood-2014-02-514760. Epub 2014 Jun 9. Review. Erratum in: Blood. 2015 Feb 5;125(6):1048.</citation>
    <PMID>24914138</PMID>
  </reference>
  <reference>
    <citation>Bayraktar UD, Champlin RE, Ciurea SO. Progress in haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2012 Mar;18(3):372-80. doi: 10.1016/j.bbmt.2011.08.001. Epub 2011 Aug 9. Review.</citation>
    <PMID>21835146</PMID>
  </reference>
  <reference>
    <citation>Parmesar K, Raj K. Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies. Adv Hematol. 2016;2016:3905907. doi: 10.1155/2016/3905907. Epub 2016 May 30. Review.</citation>
    <PMID>27313619</PMID>
  </reference>
  <reference>
    <citation>Chang YJ, Zhao XY, Huang XJ. Immune reconstitution after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Apr;20(4):440-9. doi: 10.1016/j.bbmt.2013.11.028. Epub 2013 Dec 4. Review.</citation>
    <PMID>24315844</PMID>
  </reference>
  <results_reference>
    <citation>Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, Morris LE, Solomon SR. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013 Apr 1;31(10):1310-6. doi: 10.1200/JCO.2012.44.3523. Epub 2013 Feb 19.</citation>
    <PMID>23423745</PMID>
  </results_reference>
  <results_reference>
    <citation>Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012 Dec;18(12):1859-66. doi: 10.1016/j.bbmt.2012.06.019. Epub 2012 Aug 1.</citation>
    <PMID>22863841</PMID>
  </results_reference>
  <results_reference>
    <citation>Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringdén OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20;126(8):1033-40. doi: 10.1182/blood-2015-04-639831. Epub 2015 Jun 30.</citation>
    <PMID>26130705</PMID>
  </results_reference>
  <results_reference>
    <citation>Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaños-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. doi: 10.1016/j.bbmt.2008.03.005.</citation>
    <PMID>18489989</PMID>
  </results_reference>
  <results_reference>
    <citation>Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003 Jul 15;102(2):756-62. Epub 2003 Mar 27.</citation>
    <PMID>12663454</PMID>
  </results_reference>
  <results_reference>
    <citation>Giralt S, Logan B, Rizzo D, Zhang MJ, Ballen K, Emmanouilides C, Nath R, Parker P, Porter D, Sandmaier B, Waller EK, Barker J, Pavletic S, Weisdorf D. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant. 2007 Jul;13(7):844-52. Epub 2007 May 24.</citation>
    <PMID>17580263</PMID>
  </results_reference>
  <results_reference>
    <citation>Luznik L, Engstrom LW, Iannone R, Fuchs EJ. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002;8(3):131-8.</citation>
    <PMID>11939602</PMID>
  </results_reference>
  <results_reference>
    <citation>Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec;18(12):1835-44. doi: 10.1016/j.bbmt.2012.07.003. Epub 2012 Jul 11.</citation>
    <PMID>22796535</PMID>
  </results_reference>
  <results_reference>
    <citation>Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, Li XC. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Am J Transplant. 2007 Dec;7(12):2683-92. Epub 2007 Oct 9.</citation>
    <PMID>17924994</PMID>
  </results_reference>
  <results_reference>
    <citation>Schilbach K, Schick J, Wehrmann M, Wollny G, Simon P, Schlegel PG, Eyrich M. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers. Transplantation. 2007 Jul 27;84(2):214-22. Erratum in: Transplantation. 2008 Mar 27;85(6):910. Perikles, Simon [corrected to Simon, Perikles].</citation>
    <PMID>17667813</PMID>
  </results_reference>
  <results_reference>
    <citation>Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol. 1999 Jun 1;162(11):6368-77.</citation>
    <PMID>10352249</PMID>
  </results_reference>
  <results_reference>
    <citation>Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation. 1994 Sep 15;58(5):602-10.</citation>
    <PMID>8091487</PMID>
  </results_reference>
  <results_reference>
    <citation>Al-Chaqmaqchi H, Sadeghi B, Abedi-Valugerdi M, Al-Hashmi S, Fares M, Kuiper R, Lundahl J, Hassan M, Moshfegh A. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. PLoS One. 2013 Apr 4;8(4):e60367. doi: 10.1371/journal.pone.0060367. Print 2013.</citation>
    <PMID>23593203</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, Noelle RJ, Wang L. VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res. 2014 Apr 1;74(7):1933-44. doi: 10.1158/0008-5472.CAN-13-1506.</citation>
    <PMID>24691994</PMID>
  </results_reference>
  <results_reference>
    <citation>Lines JL, Sempere LF, Broughton T, Wang L, Noelle R. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res. 2014 Jun;2(6):510-7. doi: 10.1158/2326-6066.CIR-14-0072.</citation>
    <PMID>24894088</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller HE, Guleria I, Barth RJ, Huang YH, Wang L. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7. doi: 10.1073/pnas.1420370112. Epub 2015 May 11.</citation>
    <PMID>25964334</PMID>
  </results_reference>
  <results_reference>
    <citation>Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood. 2010 Dec 16;116(25):5738-47. doi: 10.1182/blood-2010-06-287839. Epub 2010 Aug 31.</citation>
    <PMID>20807889</PMID>
  </results_reference>
  <results_reference>
    <citation>Messmann JJ, Reisser T, Leithäuser F, Lutz MB, Debatin KM, Strauss G. In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity. Blood. 2015 Aug 27;126(9):1138-48. doi: 10.1182/blood-2015-01-624163. Epub 2015 Jul 16.</citation>
    <PMID>26185131</PMID>
  </results_reference>
  <results_reference>
    <citation>Rieber N, Wecker I, Neri D, Fuchs K, Schäfer I, Brand A, Pfeiffer M, Lang P, Bethge W, Amon O, Handgretinger R, Hartl D. Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD. Bone Marrow Transplant. 2014 Apr;49(4):545-52. doi: 10.1038/bmt.2013.236. Epub 2014 Jan 27.</citation>
    <PMID>24464140</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Kenneth Meehan</investigator_full_name>
    <investigator_title>Principal Investogator- Kenneth Meehan, MD Staff Physician</investigator_title>
  </responsible_party>
  <keyword>haploidentical</keyword>
  <keyword>transplant</keyword>
  <keyword>peripheral blood</keyword>
  <keyword>allogeneic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

